Sarepta plans to submit NDA for Golodirsen Duchenne drug by year end

This article was originally published here

Sarepta Therapeutics has is planning to submit a new drug application (NDA) for accelerated approval of its duchenne muscular dystrophy (DMD) drug Golodirsen (SRP-4053).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply